 This study is to evaluate the steady-state pharmacokinetics PK and confirm the dose of the elvitegravircobicistatemtricitabinetenofovir disoproxil fumarate EVGCOBIFTCTDF single tablet regimen STR in HIV-1 infected, antiretroviral ARV treatment-naive adolescents. Safety, tolerability, and efficacy will also be evaluated through Week 48. 